Randomized, Double-Blinded, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Pharmacodynamics of BMS-986189 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 09 Mar 2017
At a glance
- Drugs BMS 986189 (Primary)
- Indications Sepsis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 24 Feb 2017 Status changed from recruiting to completed.
- 25 Apr 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Dec 2016.
- 25 Apr 2016 Status changed from not yet recruiting to recruiting.